THEBUSINESSBYTES BUREAU
MUMBAI, FEBRUARY 11, 2026
Supriya Lifescience Ltd., a
cGMP-compliant API manufacturer with a presence in over 120 countries, reported
a strong financial performance for the third quarter of FY26, registering an
11.2 per cent year-on-year rise in revenue, driven by steady global demand and
improved capacity utilisation.
The company’s revenue for Q3
FY26 stood at ₹206.44 crore, compared to ₹185.65
crore in the corresponding quarter last fiscal. EBITDA came in at ₹72.08 crore,
with an EBITDA margin of 34.9
per cent, as against
₹65.96 crore and a margin of 35.5% in Q3 FY25.
Profit After Tax (PAT) rose to ₹49.68
crore in Q3 FY26 from ₹46.78 crore a year ago. The PAT margin stood at 24.1 per cent,
compared to 25.2 per
cent in the same quarter last year.
The anesthetic segment
continued to be the primary growth driver during the first nine months of FY26,
contributing 54 per cent of total revenues, up from 48 per cent in 9M FY25. The
vitamins segment also showed improved traction, with its share rising from 11 per
cent to 12 per cent during the same period.
Geographically, growth was
largely driven by the Latin American market, with its contribution increasing
to 24 per cent from 21 per cent. North America’s share in the revenue mix
doubled to 6 per cent in Q3 FY26 from 3 per cent over the last two quarters.
Europe remained the company’s largest market, accounting for 36 per cent of
revenues, followed by Asia at 32 per cent.
Exports continued to play a
pivotal role, contributing approximately 82 per cent of total revenues during
the quarter.
Capacity utilisation improved
significantly to 76 per cent in 9M FY26 from 70 per cent in FY25, supported by
the ramp-up of Module E at the Lote Parshuram facility. To support future
expansion, the company has acquired three land parcels near its existing
manufacturing units.
Satish Wagh, Executive Chairman
and Whole Time Director, Supriya Lifescience Ltd, said, “Our performance this
quarter reflects consistent execution and sustained profitability, supported by
steady demand across key global markets. Exports continued to remain a strong
contributor, accounting for approximately 82 per cent of revenues in Q3, with
Europe forming a significant share of the business mix. Capacity utilisation
improved to around 76 per cent during 9MFY26, aided by the ramp-up of Module E
at our Lote Parshuram facility, enhancing operational efficiency and supply
reliability. As we prepare for the commercial launch of our Ambernath
formulation facility in Q4 FY26 and continue to deepen our presence in
regulated markets through backward integration and new product introductions,
we remain confident of driving stronger growth in the coming quarters.”
